Commercialization capability PK! Baekje, Innovent, Fuhong Henlin lead the way, Junshi's successor is weak? How does the unprofitable Biotech survive?

Tengsheng Bo Pharmaceutical recently announced that Luo Yongqing will resign as executive director, president and general manager of Tengsheng Bo Pharmaceutical and CEO (CHIEF Executive Officer) of Tengsheng Bo Pharmaceutical's subsidiary Tengsheng Huachuang, which will take effect

Tengsheng Bo Pharmaceutical recently announced that Luo Yongqing will resign as executive director, president and general manager of Tengsheng Bo Pharmaceutical and CEO (CHIEF Executive Officer) of Tengsheng Bo Pharmaceutical's subsidiary Tengsheng Huachuang, which will take effect

The high-level changes of Tengsheng Bo Pharmaceutical are just a microcosm

The high-level changes of Tengsheng Bo Pharmaceutical are just a microcosm

In recent years, the innovation ability of China's biopharmaceutical companies has been continuously enhanced, and more and more innovative products of enterprises have been approved for listing

With the recent release of 2022 mid-year financial reports by various pharmaceutical listed companies, the New Media Center of Pharmaceutical Economic News has sorted out the sales amount disclosed by enterprises and the size of the sales team, and from the per capita sales performance of the commercialization team, it seems to show the difference in

Industry insiders said that from Biotech to Biopharma transformation, innovative research and development capabilities are of course the "yardstick" to measure a biomedical company; At the same time, in the face of more and more arduous market tests, commercial capacity building has obviously become a competitiveness that cannot be ignored, and being able to obtain large-scale sales and stable profitability is also the core element of long-term development of enterprises

How are sales performance per capita?

Biopharma commercialization test

Biopharma commercialization test

How are sales performance per capita?

How are sales performance per capita?

The ability to innovate is the key to the sustainable development of a Biotech, but the ability to commercialize is also irreplaceable

Globally, there are only a handful

Looking back at the domestic market, some biopharmaceutical companies listed on the "18A" stock market in Hong Kong as an example are also facing the same problem

(Incomplete statistics)

(Incomplete statistics) (Incomplete statistics) (Incomplete statistics)

Among them, the number of Junshi Bio-commercialization team reached 1100 people, the sales revenue reached 310 million yuan, and the per capita sales income in the first half of the year was 280,000 yuan
.
From the perspective of the total sales performance in the first half of the year, the sales revenue of Rongchang Biology and Kangfang Biology was 328 million yuan and 300 million yuan respectively, and it seems that the income between several enterprises is equal, however, the number of commercialization teams of Rongchang Biology and Kangfang Biology is only 532 and 630 people, and the per capita sales revenue of these two companies in the first half of the year is 620,000 yuan and 470,000 yuan, respectively, and the commercialization efficiency is obviously higher
.

Among them, the number of Junshi Bio-commercialization team reached 1100 people, the sales revenue reached 310 million yuan, and the per capita sales income in the first half of the year was 280,000 yuan
.
From the perspective of the total sales performance in the first half of the year, the sales revenue of Rongchang Biology and Kangfang Biology was 328 million yuan and 300 million yuan respectively, and it seems that the income between several enterprises is equal, however, the number of commercialization teams of Rongchang Biology and Kangfang Biology is only 532 and 630 people, and the per capita sales revenue of these two companies in the first half of the year is 620,000 yuan and 470,000 yuan, respectively, and the commercialization efficiency is obviously higher
.

Junshi Bio has been successful, its PD-1 product Tripleli monoclonal antibody was officially listed for sale in February 2019, which brought 774 million yuan in sales to Junshi Bio that year, sales reached 1.
003 billion yuan in 2020, and only 412 million yuan
fell off a cliff in 2021.
Now in the first half of 2022, the sales of triprimumab were 298 million yuan, and the commercialization situation has improved, but it is still difficult to resist the pressure
of market competition.

Junshi Bio has been successful, its PD-1 product Tripleli monoclonal antibody was officially listed for sale in February 2019, which brought 774 million yuan in sales to Junshi Bio that year, sales reached 1.
003 billion yuan in 2020, and only 412 million yuan
fell off a cliff in 2021.
Now in the first half of 2022, the sales of triprimumab were 298 million yuan, and the commercialization situation has improved, but it is still difficult to resist the pressure
of market competition.

Market participants commented that if a biomedical company is compared to a "horse-drawn carriage", the ability to innovate is the horse that leads the way, and the commercialization ability is the wheel that ensures that the carriage continues to move forward, both of which should not be ignored, especially for a developing enterprise
.
"Among the current domestic biomedical enterprises, the research and development and commercialization of BeiGene and Cinda Biology seem to be more balanced
.
"

Market participants commented that if a biomedical company is compared to a "horse-drawn carriage", the ability to innovate is the horse that leads the way, and the commercialization ability is the wheel that ensures that the carriage continues to move forward, both of which should not be ignored, especially for a developing enterprise
.
"Among the current domestic biomedical enterprises, the research and development and commercialization of BeiGene and Cinda Biology seem to be more balanced
.
"

The market's division of BeiGene and Innovent Biologics as "unique files" that are different from other biomedical companies is not unfounded
.
In addition to their perfect commercialization team, it is also that they have more than one product that can achieve large-scale sales, which also allows enterprises to face the decline in the price of medical insurance negotiations in the face of products, and have more room
for maneuver.

The market's division of BeiGene and Innovent Biologics as "unique files" that are different from other biomedical companies is not unfounded
.
In addition to their perfect commercialization team, it is also that they have more than one product that can achieve large-scale sales, which also allows enterprises to face the decline in the price of medical insurance negotiations in the face of products, and have more room
for maneuver.

Taking BeiGene as an example, in the face of a large number of factors such as sharp price cuts in medical insurance negotiations and market turmoil, its revenue and profits have not been greatly affected, thanks to its global market layout, which is essentially the embodiment of
commercialization capabilities.
In the first half of 2022, even if the same PD-1 medical insurance negotiation price decline, sales revenue totaled 3.
676 billion yuan, BeiGene mainly from Baiyueze, Bai zean, Parkway Ze three drugs, basically to achieve large-scale sales of "self-hematopoiesis", per capita sales revenue in the first half of the year more than one million
.

Taking BeiGene as an example, in the face of a large number of factors such as sharp price cuts in medical insurance negotiations and market turmoil, its revenue and profits have not been greatly affected, thanks to its global market layout, which is essentially the embodiment of
commercialization capabilities.
In the first half of 2022, even if the same PD-1 medical insurance negotiation price decline, sales revenue totaled 3.
676 billion yuan, BeiGene mainly from Baiyueze, Bai zean, Parkway Ze three drugs, basically to achieve large-scale sales of "self-hematopoiesis", per capita sales revenue in the first half of the year more than one million
.

Cinda Bio's commercialization ability has been proven by the market, in the previously released 2021 annual report, Cinda Bio's product sales revenue of more than 4 billion yuan, as well as PD-1 product sales growth, have attracted market attention; Although the sales of sindilizumab in 2022 due to the "price for volume" medical insurance negotiations have encountered unprecedented pressure, the commercialization team still retains the resources of the terminal channel, and it can be seen from the data that the per capita sales revenue in the first half of the year exceeded 740,000 yuan, always at the forefront of commercialization results; In addition, Sanofi's "zero down payment" cooperation with Cinda Bio also sees the advantages
of Cinda's commercialization team.

Cinda Bio's commercialization ability has been proven by the market, in the previously released 2021 annual report, Cinda Bio's product sales revenue of more than 4 billion yuan, as well as PD-1 product sales growth, have attracted market attention; Although the sales of sindilizumab in 2022 due to the "price for volume" medical insurance negotiations have encountered unprecedented pressure, the commercialization team still retains the resources of the terminal channel, and it can be seen from the data that the per capita sales revenue in the first half of the year exceeded 740,000 yuan, always at the forefront of commercialization results; In addition, Sanofi's "zero down payment" cooperation with Cinda Bio also sees the advantages
of Cinda's commercialization team.

In addition, from the above data information, it can be seen that among the biomedical enterprises that have realized product commercialization, Zaiding Pharmaceutical, Nuocheng Jianhua, Yasheng Pharmaceutical and other enterprises are worthy of attention
in terms of commercialization efficiency.

In addition, from the above data information, it can be seen that among the biomedical enterprises that have realized product commercialization, Zaiding Pharmaceutical, Nuocheng Jianhua, Yasheng Pharmaceutical and other enterprises are worthy of attention
in terms of commercialization efficiency.

Market participants analyze that from the long-term perspective of enterprise development, blood transfusion in the capital market is only a way to solve the source of corporate funds, only by forming large-scale sales, relying on the commercialization team to make hematopoiesis independently, and undertaking the cost of the whole cycle of research and development and sales process, can a virtuous circle be formed, so as to make enough profits to make the enterprise run
more smoothly.

Market participants analyze that from the long-term perspective of enterprise development, blood transfusion in the capital market is only a way to solve the source of corporate funds, only by forming large-scale sales, relying on the commercialization team to make hematopoiesis independently, and undertaking the cost of the whole cycle of research and development and sales process, can a virtuous circle be formed, so as to make enough profits to make the enterprise run
more smoothly 。 Market participants analyze that from the long-term perspective of enterprise development, blood transfusion in the capital market is only a way to solve the source of corporate funds, only by forming large-scale sales, relying on the commercialization team to make hematopoiesis independently, and undertaking the cost of the whole cycle of research and development and sales process, can a virtuous circle be formed, so as to make enough profits to make the enterprise run
more smoothly 。 Market participants analyze that from the long-term perspective of enterprise development, blood transfusion in the capital market is only a way to solve the source of corporate funds, only by forming large-scale sales, relying on the commercialization team to make hematopoiesis independently, and undertaking the cost of the whole cycle of research and development and sales process, can a virtuous circle be formed, so as to make enough profits to make the enterprise run
more smoothly.

"The wine is also afraid of the deep alley"

Innovation does not equal commercial success

"The wine is also afraid of the deep alley"

Innovation does not equal commercial success

Innovation does not equal commercial success

For most innovative R&D companies, although there are capital injections and no short-term profit requirements, these are only temporary
.
The capital market still needs to speak by performance, and the only criterion for consideration in the end will only be the commercialization ability, the product officially enters the market, biotech's transformation to Bioopharma is gratifying, and the next commercial transformation is a new hurdle
that needs to be overcome.

For most innovative R&D companies, although there are capital injections and no short-term profit requirements, these are only temporary
.
The capital market still needs to speak by performance, and the only criterion for consideration in the end will only be the commercialization ability, the product officially enters the market, biotech's transformation to Bioopharma is gratifying, and the next commercial transformation is a new hurdle
that needs to be overcome.

"Satisfying unmet clinics with innovative drugs has achieved great commercial success
.
" The logic is closed-loop rigorous, however, the success of research and development of innovative products is not the same as commercial success; On the other side of the coin, generic/biosimilars don't necessarily mean commercial failure either
.

"Satisfying unmet clinics with innovative drugs has achieved great commercial success
.
" The logic is closed-loop rigorous, however, the success of research and development of innovative products is not the same as commercial success; On the other side of the coin, generic/biosimilars don't necessarily mean commercial failure either
.

The most typical case is Henlius
.
Previously, biosimilars were considered by the market to have no place to exist, however, in the past two years, with the phased results achieved by commercialization attempts, only one variety of trastuzumab has sold for 800 million yuan in half a year, making a market that looks like a "Red Sea" a blockbuster innovative drug
.
Although the market speculates that the commercialization results are inseparable from the global resource support of Fosun, Henlius has proved that even biosimilars can still make money, with per capita sales revenue of more than one million in the first half of the year, which has also achieved praiseworthy commercialization efficiency, and also made the capital market more looking forward to its future commercialization potential
.

The most typical case is Henlius
.
Previously, biosimilars were considered by the market to have no place to exist, however, in the past two years, with the phased results achieved by commercialization attempts, only one variety of trastuzumab has sold for 800 million yuan in half a year, making a market that looks like a "Red Sea" a blockbuster innovative drug
.
Although the market speculates that the commercialization results are inseparable from the global resource support of Fosun, Henlius has proved that even biosimilars can still make money, with per capita sales revenue of more than one million in the first half of the year, which has also achieved praiseworthy commercialization efficiency, and also made the capital market more looking forward to its future commercialization potential
.

Obviously, whether it is research, development, access or commercialization, any link may form a barrier to
competition.
Biotech's transformation of Biopharma has endless appeal, if Biotech does not have the ability to successfully commercialize its own products and turn around gorgeously, will it continue to insist?

Obviously, whether it is research, development, access or commercialization, any link may form a barrier to
competition.
Biotech's transformation of Biopharma has endless appeal, if Biotech does not have the ability to successfully commercialize its own products and turn around gorgeously, will it continue to insist?

In recent years, many pharmaceutical companies have continued to increase product breadth, enclose land and build factories, improve production and manufacturing levels, and form commercialization teams
.
However, a comprehensive review of the "self-hematopoietic" ability of the enterprise, can "sell" the product, not that the product can bring sales, but really achieve the product can form a large-scale market sales, and even after excluding the costs can really bring profits
to the enterprise.

In recent years, many pharmaceutical companies have continued to increase product breadth, enclose land and build factories, improve production and manufacturing levels, and form commercialization teams
.
However, a comprehensive review of the "self-hematopoietic" ability of the enterprise, can "sell" the product, not that the product can bring sales, but really achieve the product can form a large-scale market sales, and even after excluding the costs can really bring profits
to the enterprise.

Looking at the market, in fact, there are still many Biotech companies that concentrate on research and development, and do not ask about "city" matters
.
For example, the industry is familiar with BioNTech, Regeneron, etc.
, these companies through continuous innovation and development of licensed products, and then in the industry to establish a reputation, and finally backed by the big tree, alternative transformation to successfully commercialize
products.

Looking at the market, in fact, there are still many Biotech companies that concentrate on research and development, and do not ask about "city" matters
.
For example, the industry is familiar with BioNTech, Regeneron, etc.
, these companies through continuous innovation and development of licensed products, and then in the industry to establish a reputation, and finally backed by the big tree, alternative transformation to successfully commercialize
products.

Industry insiders pointed out that the founders of domestic innovative pharmaceutical companies are often from the technical background of scientists, and the rapid development of superimposed capital investment in the early stage of establishment with their own research and development technology and knowledge reserves; However, the success of professional technology does not mean that founders have the ability
to lead the transformation of the business toward commercialization.

Industry insiders pointed out that the founders of domestic innovative pharmaceutical companies are often from the technical background of scientists, and the rapid development of superimposed capital investment in the early stage of establishment with their own research and development technology and knowledge reserves; However, the success of professional technology does not mean that founders have the ability
to lead the transformation of the business toward commercialization.
Industry insiders pointed out that the founders of domestic innovative pharmaceutical companies are often from the technical background of scientists, and the rapid development of superimposed capital investment in the early stage of establishment with their own research and development technology and knowledge reserves; However, the success of professional technology does not mean that founders have the ability
to lead the transformation of the business toward commercialization.

This also dooms the arduous process of corporate transformation, between corporate management, between research and development and commercialization, there may be differences
in strategic thinking.
Whether it is the earlier changes of the commercial leader of Junshi Bio for many times, or the Tengsheng Bo Pharmaceutical mentioned at the beginning of this article, the replacement of the position of commercialization leader or general manager has also triggered speculation in
the capital market about the commercialization ability of enterprises.

This also dooms the arduous process of corporate transformation, between corporate management, between research and development and commercialization, there may be differences
in strategic thinking.
Whether it is the earlier changes of the commercial leader of Junshi Bio for many times, or the Tengsheng Bo Pharmaceutical mentioned at the beginning of this article, the replacement of the position of commercialization leader or general manager has also triggered speculation in
the capital market about the commercialization ability of enterprises.

At the same time, under the cold winter of the capital market, some companies are forced by competitive pressure and are also looking for short-term opportunities for
realization.
Not long ago, Genting ShinYao announced that it has signed an agreement with Impomedics, a wholly-owned subsidiary of Gilead, to transfer to Impomedics the exclusive right to develop and commercialize its core Trop-2 ADC drug Trodelvy, which was previously imported from Omniomedics, in Greater China, South Korea and some Southeast Asian countries; Subsequently, the company's chief executive officer (CEO) Dr.
Bo Kerui announced his resignation, further raising market concerns
about biotech's commercial transformation.

At the same time, under the cold winter of the capital market, some companies are forced by competitive pressure and are also looking for short-term opportunities for
realization.
Not long ago, Genting ShinYao announced that it has signed an agreement with Impomedics, a wholly-owned subsidiary of Gilead, to transfer to Impomedics the exclusive right to develop and commercialize its core Trop-2 ADC drug Trodelvy, which was previously imported from Omniomedics, in Greater China, South Korea and some Southeast Asian countries; Subsequently, the company's chief executive officer (CEO) Dr.
Bo Kerui announced his resignation, further raising market concerns
about biotech's commercial transformation.

Wine is also afraid of deep alleys, success has a diversified definition, not every company must pursue commercial success
.
Focusing on unmet clinical needs, consolidating original high-end technologies, and building a research and development platform with independent intellectual property rights, biomedical enterprises can also gain a firm foothold
in the cycle of the industrial chain.

Wine is also afraid of deep alleys, success has a diversified definition, not every company must pursue commercial success
.
Focusing on unmet clinical needs, consolidating original high-end technologies, and building a research and development platform with independent intellectual property rights, biomedical enterprises can also gain a firm foothold
in the cycle of the industrial chain.
Wine is also afraid of deep alleys, success has a diversified definition, not every company must pursue commercial success
.
Focusing on unmet clinical needs, consolidating original high-end technologies, and building a research and development platform with independent intellectual property rights, biomedical enterprises can also gain a firm foothold
in the cycle of the industrial chain.
Wine is also afraid of deep alleys, success has a diversified definition, not every company must pursue commercial success
.
Focusing on unmet clinical needs, consolidating original high-end technologies, and building a research and development platform with independent intellectual property rights, biomedical enterprises can also gain a firm foothold
in the cycle of the industrial chain.

In the face of the cold winter of the capital market, after gaining a firm foothold, the process may be smoother
.

In the face of the cold winter of the capital market, after gaining a firm foothold, the process may be smoother
.